<![CDATA[Genmab — Maj 2026]]>AMGEN Q1 2026 TEPEZZA® (teprotumumab-trbw) sales increased 29% year-over-year to $490 million in the first quarter, driven by a 22% impact from higher inventory levels and higher net selling price. https://www.amgen.com/newsroom/press-releases/2026/04/c-o-r-r-e-c-t-i-o-n----amgen

]]>https://dev.proinvestor.com/forum/topic/399208/genmab-maj-2026RSS for NodeSun, 07 Jun 2026 06:30:01 GMTFri, 01 May 2026 05:35:52 GMT60<![CDATA[Reply to Genmab — Maj 2026 on Fri, 15 May 2026 11:30:01 GMT]]>China's NMPA has approved epcoritamab (Epkinly) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (FL). This marks epcoritamab's first approval in China. https://medj.cn/articleDetails?id=728&module=innovationTracker

]]>https://dev.proinvestor.com/forum/post/7687074https://dev.proinvestor.com/forum/post/7687074Fri, 15 May 2026 11:30:01 GMT<![CDATA[Reply to Genmab — Maj 2026 on Fri, 15 May 2026 10:59:34 GMT]]>small new trial - Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma https://clinicaltrials.gov/study/NCT07588698

]]>https://dev.proinvestor.com/forum/post/7687069https://dev.proinvestor.com/forum/post/7687069Fri, 15 May 2026 10:59:34 GMT<![CDATA[Reply to Genmab — Maj 2026 on Fri, 15 May 2026 10:58:05 GMT]]>University looking to test Dara in lung cancer... https://clinicaltrials.gov/study/NCT06015724 - don't want to bring up Hexabody-CD38 again, but...

]]>https://dev.proinvestor.com/forum/post/7687068https://dev.proinvestor.com/forum/post/7687068Fri, 15 May 2026 10:58:05 GMT<![CDATA[Reply to Genmab — Maj 2026 on Fri, 15 May 2026 09:14:28 GMT]]>Stuck in traffic: a bispecific antibody-mediated immune re-engagement after allogeneic stem cell transplantation https://haematologica.org/article/view/14183 (click on PDF to read article)

]]>https://dev.proinvestor.com/forum/post/7687072https://dev.proinvestor.com/forum/post/7687072Fri, 15 May 2026 09:14:28 GMT<![CDATA[Reply to Genmab — Maj 2026 on Fri, 15 May 2026 08:57:56 GMT]]>Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6 https://www.sciencedirect.com/science/article/pii/S215226502600042X

]]>https://dev.proinvestor.com/forum/post/7687073https://dev.proinvestor.com/forum/post/7687073Fri, 15 May 2026 08:57:56 GMT<![CDATA[Reply to Genmab — Maj 2026 on Thu, 14 May 2026 07:33:19 GMT]]>Tak for den @peter12

]]>https://dev.proinvestor.com/forum/post/7687070https://dev.proinvestor.com/forum/post/7687070Thu, 14 May 2026 07:33:19 GMT<![CDATA[Reply to Genmab — Maj 2026 on Wed, 13 May 2026 19:28:43 GMT]]>Interessant artikel om konkurrerende produkt til peto, hvor udvidelsen diskuteres https://seekingalpha.com/article/4904035-bicara-therapeutics-inc-bcax-presents-at-bank-of-america-global-healthcare-conference-2026

]]>https://dev.proinvestor.com/forum/post/7687071https://dev.proinvestor.com/forum/post/7687071Wed, 13 May 2026 19:28:43 GMT<![CDATA[Reply to Genmab — Maj 2026 on Wed, 13 May 2026 11:52:27 GMT]]>Novo Nordisk er steget 30% på relativ kort tid - men hvad ligger bag stigningen? Hør også om DSV's AI-gevinster frem mod 2030, Genmab-kursfald, høje oliepriser samt meget mere i ugens afsnit af Investeringspodcasten. https://proinvestor.com/boards/132326

]]>https://dev.proinvestor.com/forum/post/7687067https://dev.proinvestor.com/forum/post/7687067Wed, 13 May 2026 11:52:27 GMT<![CDATA[Reply to Genmab — Maj 2026 on Tue, 12 May 2026 17:56:31 GMT]]>Ligner pump and dump der startede med den mærkelige nedtur på regnskabet. Vi må se de kommende dage.

]]>https://dev.proinvestor.com/forum/post/7687066https://dev.proinvestor.com/forum/post/7687066Tue, 12 May 2026 17:56:31 GMT<![CDATA[Reply to Genmab — Maj 2026 on Tue, 12 May 2026 15:52:09 GMT]]>Ja, det er sjovt som aktien springer engang imellem?..... Der skal også snart til at ske noget med kursen. Dette limbo halløj kan ikke blive ved - vi har ASCO om 3 ugers tid....

]]>https://dev.proinvestor.com/forum/post/7687063https://dev.proinvestor.com/forum/post/7687063Tue, 12 May 2026 15:52:09 GMT<![CDATA[Reply to Genmab — Maj 2026 on Tue, 12 May 2026 12:41:12 GMT]]>Skete med åbning i US i et ellers surt marked.

]]>https://dev.proinvestor.com/forum/post/7687062https://dev.proinvestor.com/forum/post/7687062Tue, 12 May 2026 12:41:12 GMT<![CDATA[Reply to Genmab — Maj 2026 on Tue, 12 May 2026 12:32:01 GMT]]>Mærkelige spring i kursen. Skete for en uges tid siden også i US.

]]>https://dev.proinvestor.com/forum/post/7687061https://dev.proinvestor.com/forum/post/7687061Tue, 12 May 2026 12:32:01 GMT<![CDATA[Reply to Genmab — Maj 2026 on Tue, 12 May 2026 03:40:35 GMT]]>from yesterday- Deutsche Bank analyst Emmanuel Papadakis lowered the firm's price target on Genmab (GMAB) to DKK 2,250 from DKK 2,400 and keeps a Buy rating on the shares. 11-5-26

]]>https://dev.proinvestor.com/forum/post/7687058https://dev.proinvestor.com/forum/post/7687058Tue, 12 May 2026 03:40:35 GMT<![CDATA[Reply to Genmab — Maj 2026 on Tue, 12 May 2026 03:37:19 GMT]]>RYBREVANT®▼ (amivantamab) with LAZCLUZE™▼ (lazertinib) is accepted for use within NHS Scotland as a first-line treatment for adult patients with untreated advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations https://www.jnj.com/innovativemedicine/uk/media-center/press-releases/rybrevant-amivantamab-with-lazcluze-lazertinib-is-accepted-for-use-within-nhs-scotland

]]>https://dev.proinvestor.com/forum/post/7687065https://dev.proinvestor.com/forum/post/7687065Tue, 12 May 2026 03:37:19 GMT<![CDATA[Reply to Genmab — Maj 2026 on Mon, 11 May 2026 08:20:04 GMT]]>Stockwatch DK
@StockwatchDK
$GMAB
UBS reiterates its Buy rating on Genmab with a price target of DKK 2,600, saying the Q1 results were broadly in line with expectations. https://x.com/StockwatchDK/status/2053765010724159767

]]>https://dev.proinvestor.com/forum/post/7687059https://dev.proinvestor.com/forum/post/7687059Mon, 11 May 2026 08:20:04 GMT<![CDATA[Reply to Genmab — Maj 2026 on Mon, 11 May 2026 03:50:32 GMT]]>Genmab får gentaget "køb" hos Jefferies efter frustrationsreaktioner på forskningsnyt https://proinvestor.com/investornyt/1442956/genmab-far-gentaget-kob-hos-jefferies-efter-frustrationsreaktioner-pa-forskningsnyt

]]>https://dev.proinvestor.com/forum/post/7687057https://dev.proinvestor.com/forum/post/7687057Mon, 11 May 2026 03:50:32 GMT<![CDATA[Reply to Genmab — Maj 2026 on Mon, 11 May 2026 03:30:59 GMT]]>TD Cowen Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $32

May 8 2026

]]>https://dev.proinvestor.com/forum/post/7687075https://dev.proinvestor.com/forum/post/7687075Mon, 11 May 2026 03:30:59 GMT<![CDATA[Reply to Genmab — Maj 2026 on Mon, 11 May 2026 03:30:14 GMT]]>Morningstart :- Genmab Earnings: Strong Patient Uptake and Diverse Late-Stage Pipeline Support Positive Outlook

Rachel Elfman
May 11, 2026 - We maintain our fair value estimate of dkk 2.650

]]>https://dev.proinvestor.com/forum/post/7687064https://dev.proinvestor.com/forum/post/7687064Mon, 11 May 2026 03:30:14 GMT<![CDATA[Reply to Genmab — Maj 2026 on Sat, 09 May 2026 11:10:06 GMT]]>The study of GEN1057 has been terminated due to marginal anti-tumor activity not supporting further development, Ref ClinicalTrials (NCT06573294) 8/5 2026. This was one of the 100% owned Genmab antibodies. The study started 28/8 2024 and stopped after enrolling 23 patients.

]]>https://dev.proinvestor.com/forum/post/7687060https://dev.proinvestor.com/forum/post/7687060Sat, 09 May 2026 11:10:06 GMT<![CDATA[Reply to Genmab — Maj 2026 on Sat, 09 May 2026 05:38:35 GMT]]>Morgan Stanley lowered the firm's price target on Genmab (GMAB) to $33 from $34 and keeps an Equal Weight rating on the shares. 8-5-26

]]>https://dev.proinvestor.com/forum/post/7687055https://dev.proinvestor.com/forum/post/7687055Sat, 09 May 2026 05:38:35 GMT<![CDATA[Reply to Genmab — Maj 2026 on Sat, 09 May 2026 05:33:23 GMT]]>Denecimig excels at reducing bleeds in hemophilia A patients: Study https://hemophilianewstoday.com/news/denecimig-excels-reducing-bleeds-hemophilia-a-patients/

]]>https://dev.proinvestor.com/forum/post/7687052https://dev.proinvestor.com/forum/post/7687052Sat, 09 May 2026 05:33:23 GMT<![CDATA[Reply to Genmab — Maj 2026 on Sat, 09 May 2026 04:36:45 GMT]]>NICE issues Final Draft Guidance recommending that RYBREVANT®▼ (amivantamab) with carboplatin and pemetrexed can be used during a managed access period for untreated advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations in adults https://www.jnj.com/innovativemedicine/uk/media-center/press-releases/nice-guidance-rybrevant-nsclc-egfr-exon20-managed-access

]]>https://dev.proinvestor.com/forum/post/7687053https://dev.proinvestor.com/forum/post/7687053Sat, 09 May 2026 04:36:45 GMT<![CDATA[Reply to Genmab — Maj 2026 on Sat, 09 May 2026 03:05:04 GMT]]>Major Shareholder Announcement https://proinvestor.com/investornyt/1442512/major-shareholder-announcement

]]>https://dev.proinvestor.com/forum/post/7687050https://dev.proinvestor.com/forum/post/7687050Sat, 09 May 2026 03:05:04 GMT<![CDATA[Reply to Genmab — Maj 2026 on Fri, 08 May 2026 18:24:50 GMT]]>Orbis udnyttede udsalget og
er nu på 5,08%.

]]>https://dev.proinvestor.com/forum/post/7687049https://dev.proinvestor.com/forum/post/7687049Fri, 08 May 2026 18:24:50 GMT